Synthetic Design Lab Raises $20M in Funding for Novel Cancer Therapeutic Platform
Synthetic Design Lab, a San Francisco-based company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has secured $20 million in funding to advance its groundbreaking SYNTHBODY therapeutic platform.
The funding round was led by Playground Global and Godfrey Capital, with plans to progress the company’s first therapeutic into clinical trials in the coming year.
Under the leadership of CEO Daniel S. Chen and CSO Ramesh Baliga, Ph.D., Synthetic Design Lab is revolutionizing ADCs with its SYNTHBODY platform. This innovative technology is designed to enhance targeted payload delivery, potentially enhancing the efficacy, safety, and versatility of existing ADCs.
Dr. Daniel S. Chen, a prominent physician-scientist and pioneer in cancer immunotherapy and protein engineering, brings a wealth of experience to the company. With a background at Genentech developing immune modulators, anti-angiogenics, and ADCs, Dr. Chen played a key role in the clinical development of atezolizumab (TECENTRIQ®), the first approved PD-L1 inhibitor. He is also actively involved in the Society for Immunotherapy of Cancer (SITC) and other industry organizations.
Overall, Synthetic Design Lab’s focus on innovation and cutting-edge technology positions them as a key player in the fight against cancer, with the recent funding enabling them to further advance their therapeutic solutions.
FinSMEs
